FDA Approves First Interchangeable Biosimilars To Prolia And Xgeva To Treat Certain Types Of Osteoporosis And Prevent Bone Events In Cancer
Bone Density Medication:
When releasing news of the drug, FDA officials noted that after 12 doses, its powerful bone-building powers wane, and patients should switch to a second treatment that reduces bone breakdown. The U.S. Food and Drug Administration (FDA) approved the new medication romosozumab (brand name Evenity), from the drugmaker Amgen, which appears to dramatically boost bone density. Amgen …